StockpollyBeta
Get App
Popularity #1,387
NKTR · NASDAQ · Biotechnology

Nektar Therapeutics (NKTR)

Develops investigational immune-modulating medicines for autoimmune disease and cancer.

$61.45
After hours+0.51 (+0.84%)
At close$60.94(−8.83%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue242422232429101112221110
Cost of revenue12791048000000
Gross profit121713142021101112221110
57504964547554743414952
Research & development243027303529303027303639
211720211917241716111313
Selling & marketing000000000000
General & administrative211720211917241716111313
Other expenses1131130−39000001
Operating income−45−34−35−50−3414−45−36−32−19−38−42
−1−9−1−3−3−7−6−6−4−17−72
Interest income554433323349
Interest expense67666105561087
Other non-operating income−52−4−4−3−3−3−2−27−10
Income before tax−46−42−37−52−377−51−42−36−36−45−40
Income tax expense000000000000
Net income from continuing operations−46−42−37−52−377−51−42−36−36−45−40
Other adjustments000000000000
Net income−46−42−37−52−377−51−42−36−36−45−41
EPS, basic−$3.61−$3.30−$2.83−$3.76−$2.66$0.52−$3.62−$2.95−$1.87−$1.78−$1.82−$1.23
EPS, diluted−$3.61−$3.30−$2.83−$3.76−$2.66$0.51−$3.62−$2.95−$1.87−$1.78−$1.82−$1.23
Weighted average shares, basic131313141414141414202533
Weighted average shares, diluted131313141414141414202533
EBITDA−38−34−30−44−3017−41−34−29−26−37−42
Depreciation & amortization222110000000
EBIT−40−35−31−46−3117−41−34−30−26−37−42